Search research articles
Contact Us
Filters
Showing results (261-270 of 319) with videos related to
Page
of 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2005
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
Matthew R Smith, Fairooz Kabbinavar, Fred Saad, et al.
European Urology
|
March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 17, 2025
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024
Ursula M Vogl, Sara Merler, Antonio Angrisani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2021
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Matthew R Smith, Shibu Thomas, Michael Gormley, et al.
European Urology Oncology
|
December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer
Eric J Small, Kim N Chi, Simon Chowdhury, et al.
The Oncologist
|
November 30, 2017
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
Oliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, et al.
Translational Psychiatry
|
February 18, 2022
Metabolic effects of the schizophrenia-associated 3q29 deletion
Rebecca M Pollak, Ryan H Purcell, Timothy P Rutkowski, et al.
European Urology
|
April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Fred Saad, Maha H A Hussain, Bertrand Tombal, et al.
Circulation. Cardiovascular Genetics
|
January 21, 2016
Endothelial Cell Bioenergetics and Mitochondrial DNA Damage Differ in Humans Having African or West Eurasian Maternal Ancestry
David M Krzywanski, Douglas R Moellering, David G Westbrook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Maha Hussain, Bertrand Tombal, Fred Saad, et al.
Page
of 32
Search research articles
Search
Showing results (261-270 of 319) with videos related to
Sort By:
Page
of 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2005
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
Matthew R Smith, Fairooz Kabbinavar, Fred Saad, et al.
European Urology
|
March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 17, 2025
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024
Ursula M Vogl, Sara Merler, Antonio Angrisani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2021
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Matthew R Smith, Shibu Thomas, Michael Gormley, et al.
European Urology Oncology
|
December 10, 2023
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer
Eric J Small, Kim N Chi, Simon Chowdhury, et al.
The Oncologist
|
November 30, 2017
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
Oliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, et al.
Translational Psychiatry
|
February 18, 2022
Metabolic effects of the schizophrenia-associated 3q29 deletion
Rebecca M Pollak, Ryan H Purcell, Timothy P Rutkowski, et al.
European Urology
|
April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Fred Saad, Maha H A Hussain, Bertrand Tombal, et al.
Circulation. Cardiovascular Genetics
|
January 21, 2016
Endothelial Cell Bioenergetics and Mitochondrial DNA Damage Differ in Humans Having African or West Eurasian Maternal Ancestry
David M Krzywanski, Douglas R Moellering, David G Westbrook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2023
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Maha Hussain, Bertrand Tombal, Fred Saad, et al.
Page
of 32